Guo Han-Wen, Lin Liang-Ting, Chen Po-Hsiung, Ho Meng-Huan, Huang Wan-Ting, Lee Yi-Jang, Chiou Shih-Hwa, Hsieh Yei-San, Dong Chen-Yuan, Wang Hsing-Wen
Institute of Biophotonics, National Yang-Ming University, Taipei 112, Taiwan; Department of Physics, National Taiwan University, Taipei 106, Taiwan.
Department of Biomedical Imaging and Radiological Science, National Yang-Ming University, Taipei 112, Taiwan.
Photodiagnosis Photodyn Ther. 2015 Sep;12(3):504-10. doi: 10.1016/j.pdpdt.2015.04.007. Epub 2015 Apr 29.
The treatment of gliomas poses significant clinical challenges due to resistance to chemo and radiation therapy, and treatment side effects. Metronomic photodynamic therapy (mPDT), which involves long treatment time with low fluence rate and multiple or continuous photosensitizer administrations, has potential in treating gliomas without threatening the quality of life and has been demonstrated in rats and rabbits. mPDT in small animals such as mouse is not yet shown due to lack of lightweight illumination device for long periods of time.
We presented low fluence rate (3mW/cm(2)) and long duration (3.7h) PDT treatment in a nude mouse model of human glioblastoma by using organic light emitting diode (OLED) with single dose of 5-aminolevulinic acid (ALA) administration as photosensitizer. Tumor volume was measured using bioluminescent imaging and the animal survival time was recorded. Additionally, we have performed limited PDT dosimetric measurements of PpIX fluorescence, tumor oxygenation and hemoglobin concentration in 3 PDT mice.
For animals with similar pre- and immediate post-light tumor volume, the averaged total survival time of PDT mice is 40.5±9.2 days that are significantly longer than the control mice (26.0±2.0 days). The post-light survival time of PDT mice is 14.3±5.9 days that are marginally longer than the control group (8.0±0.0 days). In the dosimetric measurement, good maintenance of PpIX fluorescence in one PDT mouse has relatively improved survival time, compared with the other two PDT mice (i.e., 24 days versus 16 and 17 days).
This pilot study demonstrated the feasibility of low-fluence rate and long treatment time of ALA-PDT using OLED without anesthetization of animals. The response of PDT treated animals with similar pre- and post-light tumor volume is encouraging to show a longer survival time than the controls. The dosimetric indices such as photosensitizer fluorescence and tissue oxygenation would help understand the possible treatment barriers for further improvement of treatment plans.
由于对化疗和放疗的耐药性以及治疗副作用,胶质瘤的治疗面临重大临床挑战。节拍式光动力疗法(mPDT),即长时间低通量率治疗以及多次或连续给予光敏剂,在不影响生活质量的情况下治疗胶质瘤具有潜力,并且已在大鼠和兔子身上得到验证。由于缺乏长时间使用的轻型照明设备,尚未在小鼠等小动物身上展示mPDT。
我们通过使用有机发光二极管(OLED),以单剂量给予5-氨基酮戊酸(ALA)作为光敏剂,在人胶质母细胞瘤裸鼠模型中进行了低通量率(3mW/cm²)和长时间(3.7小时)的光动力疗法治疗。使用生物发光成像测量肿瘤体积,并记录动物存活时间。此外,我们对3只接受光动力疗法的小鼠进行了有限的光动力疗法剂量学测量,包括原卟啉IX(PpIX)荧光、肿瘤氧合和血红蛋白浓度。
对于光照射前后肿瘤体积相似的动物,光动力疗法治疗小鼠的平均总存活时间为40.5±9.2天,显著长于对照小鼠(26.0±2.0天)。光动力疗法治疗小鼠的光照射后存活时间为14.3±5.9天,略长于对照组(8.0±0.0天)。在剂量学测量中,与另外两只光动力疗法治疗小鼠相比,一只光动力疗法治疗小鼠中PpIX荧光的良好维持使其存活时间相对延长(即24天对16天和17天)。
这项初步研究证明了在不麻醉动物的情况下,使用OLED进行低通量率和长时间ALA-光动力疗法治疗的可行性。光动力疗法治疗的动物在光照射前后肿瘤体积相似,其反应令人鼓舞,显示出比对照组更长的存活时间。诸如光敏剂荧光和组织氧合等剂量学指标将有助于理解可能的治疗障碍,以进一步改进治疗方案。